Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by canadapieton Aug 20, 2023 3:18am
119 Views
Post# 35596774

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:IF there is no PR tomorrow

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:IF there is no PR tomorrow
Correct over the entire line!!!!!
Except the last sentence, because it was the right idea to do .....SELL!!!!

Now it is a waiting/hoping thing again.
Normally, i wouldn't follow it anymore, but i was in for so long, and there is "something" in my mind that says there must be "something", maybe, eventually........!
I will see how they manage to come out of that disastrous terrible fatal?? situation!!
For now, my money stays on the sideline (like all those insiders wisely decided.....!!!!) 

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:IF there is no PR tomorrow 
The valuation represent exasperation from some shareholders. This management is always short of what they promised. The last real positive news for Thera was the approval of Trogarzo, at least it was positive on paper. Since this news that propelled the stock price, it is down and down and down. Sales of Trogarzo never came close to minimal expectations, then we got all this NASH smokescreen, first for HIV patients, then for general population, small phase III, big phase III, then phase II/III. All that failed because our big pharma CEO was never able to convince ant partner. Then you have the TH1902 phase I blunder, with an ill concieved protocol that lasted three times what they said it would. In parallel, Tanguay believed his own BS and borrowed money on the back of Trogarzo's approval instead of doing a financing at a ggod price. Then Levesque came in with this debt problem, but nonetheless hired staff as if he was still working at Pfizer. And now the company is in bad financial position with Marathon holding them, and they failed their latest promises on restarting TH1902's trial. So yes, some decided that this company can no longer be trusted. That does not mean that the situation is lost and selling was the right idea, but it is understandable because they are unable to deliver on simple timelines.
<< Previous
Bullboard Posts
Next >>